Status:
COMPLETED
Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
Lead Sponsor:
Fondazione Italiana Linfomi - ETS
Conditions:
Cutaneous T Cell Lymphoma
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Eligibility:
All Genders
18+ years
Brief Summary
This study is designed to describe the clinical activity and safety profile of mogamulizumab at standard dose in the treatment of CTCL patients in real world setting
Detailed Description
Mogamulizumab (anti-CCR4) has been recently approved and reimbursed in Italy for the treatment of Cutaneous T-cell lymphoma (CTCL) after 1 previous systemic treatment based on the favourable results o...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria (Trautinger et al, Eur J Cancer, 2017)
- Age ≥18 years
- Have failed at least one previous line of systemic therapy
- Have received mogamulizumab in real life setting after the approval and reimbursement of the drug from the National Health System in December 2020
- Have received first dose of mogamulizumab between 01/01/2021 and 31/01/2023
- Have received mogamulizumab at the standard approved dose (1.0 mg/kg intravenously on days 1, 8, 15 and 22 of the first cycle and on days 1 and 15 of subsequent cycles)
- Availability of complete medical records.
Exclusion
- • Patients not meeting the above-mentioned inclusion criteria
Key Trial Info
Start Date :
June 6 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 11 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06113081
Start Date
June 6 2024
End Date
November 11 2025
Last Update
December 24 2025
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinica di Ematologia - AOU Ospedali Riuniti delle Marche
Ancona, Italy
2
S.C. Ematologia e Trapianto emopoietico - A.O. S.Giuseppe Moscati
Avellino, Italy
3
Clinica Dermatologia - A.O.U. Policlinico Consorziale
Bari, Italy
4
U.O.C. Ematologia - IRCCS Istituto Tumori Giovanni Paolo II
Bari, Italy